Comparison of the effectiveness of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the treatment of COVID-19 moderate hospitalized patients with severe high-risk factors

<bold>Objective</bold> This study aimed to compare the effectiveness of Simnotrelvir/Ritonavir (SR) and Nirmatrelvir/Ritonavir (NR) in the treatment of medium-sized COVID-19 with high-risk factors. <bold>Methods</bold> All 46 patients received antiviral and conventional symptomatic treatment, the patients were divided into two groups: the SR group (n=24) and the NR group (n=22). The main observation endpoints were the conversion rate of severe disease, hospitalization time, and recovery rate of clinical symptoms. The adverse drug reactions were observed as well. <bold>Results</bold> 46 patients did not progress to severe disease after receiving antiviral therapy. The hospitalization time was (6.33±1.90) days in the SR group and (6.45±2.30) days in the NR group. 76.47% of patients in the SR group had pulmonary inflammation suggesting absorption, and 80.00% in the NR group. There were no statistical differences between the two groups. No adverse events beyond the instructions were observed in the two groups. <bold>Conclusion</bold> In this study, we found that 0% of patients treated with Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir had severe disease. There were no significant differences in average hospitalized time, CT inflammation absorption time, and absorption rate between the two groups. No adverse drug reactions were observed during hospitalization, and no new safety events were observed, suggesting the excellent effectiveness and safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in preventing the progression of medium-sized COVID-19 to severe disease.